Beyond Limitations: New Microfluidics Platform for Cancer Drug Screening and Profiling

May 29th, 2018 Posted by Publications 0 thoughts on “Beyond Limitations: New Microfluidics Platform for Cancer Drug Screening and Profiling”

High-attrition rates during clinical development of new cancer therapies still persist. A new 3D ex vivo microfluidics platform shall now enhance cancer drug screening and early development process by creating cancer models which predict clinical outcomes with significantly increased reliability.

Read the full article

Leave a Reply

Subscribe to Blog

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Our Company
Follow Us

 

© Copyright AMS Biotechnology (Ltd) / University of Strathclyde / ScreenIn3D. All rights reserved 2018.